LTW 980
Alternative Names: LTW-980Latest Information Update: 28 Jan 2023
Price :
$50 *
At a glance
- Originator Novartis
- Class Antihyperlipidaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hypertriglyceridaemia
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for phase-I development in Hypertriglyceridaemia in Switzerland